Have a feature idea you'd love to see implemented?
Let us know!
Price (delayed)
$53.23
Market cap
$674.61M
P/E Ratio
35.97
Dividend/share
$0.93
EPS
$1.48
Enterprise value
$623.15M
IRADIMED CORPORATION is a leader in the development of innovative magnetic resonance imaging ('MRI') compatible medical devices. It's the only known provider of a non-magnetic intravenous ('IV') infusion pump system
Highlights
The company's debt has shrunk by 88% YoY and by 29% QoQ
Iradimed's EPS has increased by 15% YoY
IRMD's price to earnings (P/E) is 43% lower than its 5-year quarterly average of 63.4 but 11% higher than its last 4 quarters average of 32.4
Iradimed's quick ratio has decreased by 5% from the previous quarter
Key stats
What are the main financial stats of IRMD
Market
Valuations
Earnings
Shares outstanding
12.67M
Market cap
$674.61M
Enterprise value
$623.15M
Price to earnings (P/E)
35.97
Price to book (P/B)
8.08
Price to sales (P/S)
9.46
EV/EBIT
26.39
EV/EBITDA
25.5
EV/Sales
8.74
Revenue
$71.31M
EBIT
$23.61M
EBITDA
$24.44M
Free cash flow
$17.16M
Per share
Balance sheet
Liquidity
EPS
$1.48
Free cash flow per share
$1.35
Book value per share
$6.59
Revenue per share
$5.63
TBVPS
$7.21
Total assets
$94.25M
Total liabilities
$10.81M
Debt
$264,075
Equity
$83.43M
Working capital
$66.22M
Debt to equity
0
Current ratio
9.21
Quick ratio
7.7
Net debt/EBITDA
-2.11
Margins
Efficiency
Dividend
EBITDA margin
34.3%
Gross margin
77.1%
Net margin
26.1%
Operating margin
29.9%
Return on assets
20.4%
Return on equity
24%
Return on invested capital
76.5%
Return on capital employed
27.4%
Return on sales
33.1%
Dividend yield
1.75%
DPS
$0.93
Payout ratio
62.8%
IRMD stock price
How has the Iradimed stock price performed over time
Intraday
0%
1 week
2.39%
1 month
4.47%
1 year
30.47%
YTD
12.13%
QTD
5.85%
Financial performance
How have Iradimed's revenue and profit performed over time
Revenue
$71.31M
Gross profit
$55M
Operating income
$21.32M
Net income
$18.63M
Gross margin
77.1%
Net margin
26.1%
The gross profit is up by 15% YoY and by 2.5% QoQ
Iradimed's net income has increased by 14% YoY
The company's revenue rose by 13% YoY and by 2.6% QoQ
The company's operating income rose by 11% YoY
Growth
What is Iradimed's growth rate over time
Valuation
What is Iradimed stock price valuation
P/E
35.97
P/B
8.08
P/S
9.46
EV/EBIT
26.39
EV/EBITDA
25.5
EV/Sales
8.74
IRMD's price to earnings (P/E) is 43% lower than its 5-year quarterly average of 63.4 but 11% higher than its last 4 quarters average of 32.4
Iradimed's EPS has increased by 15% YoY
The price to book (P/B) is 26% higher than the 5-year quarterly average of 6.4 and 6% higher than the last 4 quarters average of 7.6
Iradimed's equity has increased by 12% YoY and by 4.7% QoQ
The company's revenue rose by 13% YoY and by 2.6% QoQ
The price to sales (P/S) is 10% higher than the last 4 quarters average of 8.6 and 5% higher than the 5-year quarterly average of 9.0
Efficiency
How efficient is Iradimed business performance
Iradimed's return on equity has increased by 3.4% YoY but it has decreased by 2.8% QoQ
Iradimed's return on invested capital has decreased by 2.5% YoY
The company's return on assets rose by 3% YoY but it fell by 2.4% QoQ
Iradimed's return on sales has decreased by 2.6% QoQ
Dividends
What is IRMD's dividend history
DPS
$0.93
Dividend yield
1.75%
Payout ratio
62.8%
Recent dividends
Special dividends are included in TTM DPS and yield
Financial health
How did Iradimed financials performed over time
Iradimed's total liabilities has decreased by 16% YoY but it has increased by 5% QoQ
Iradimed's total assets has increased by 8% YoY and by 4.8% from the previous quarter
The company's debt is 100% lower than its equity
The debt to equity has plunged by 100% YoY
The company's debt has shrunk by 88% YoY and by 29% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.